Arrowhead (ARWR) Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the treatment of familial chylomicronemia syndrome, a severe and rare genetic disease. The FDA provided a Prescription Drug User Fee Act action date of November 18, and indicated it is not currently planning to hold an advisory committee meeting. Arrowhead also intends to submit applications for approval of investigational plozasiran for the treatment of patients with FCS to additional regulatory authorities in 2025.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Sarepta’s Elevidys launch remains strong with solid beat, says JPMorgan
- Arrowhead doses 1st patients in study of ARO-INHBE for obesity treatment
- Ionis FDA approval a positive for Arrowhead, says H.C. Wainwright
- Leadership Transition at Arrowhead Pharmaceuticals’ Board
- Arrowhead announces interim results from ARO-CFB study